Pamidronate

Pamidronate is filed as Bisphosphonate. The sections below restate public label fields stored for this profile.

Class
Bisphosphonate
Route
INTRAVENOUS
Dosage forms
• Renal failure: Do not exceed single doses of 90 mg pamidronate disodium. Assess renal function before each treatment. In patients with bone metastases with severe renal impairment, use of pamidronate disodium is not recommended. ( 5.1 ) • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.2 , 8.1 , 8.3 ) • Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. ( 5.3 ) • Osteonecrosis of the jaw: Perform preventive dental procedures prior to initiating pamidronate disodium. Avoid invasive procedures if possible in patients receiving pamidronate disodium. ( 5.4 ) • Atypical fractures of the femur can occur after minimal or no trauma. Evaluate patients with thigh or groin pain for possible fracture. ( 5.5 )
Generic available
Yes
Manufacturer
Mylan Institutional LLC

Approved uses

Pamidronate disodium is a bisphosphonate indicated for the treatment of: • moderate or severe hypercalcemia associated with malignancy, with or without bone metastases ( 1.1 ) • patients with moderate to severe Paget’s disease of bone ( 1.2 ) • osteolytic bone metastases of breast cancer or osteolytic lesions of multiple myeloma, in conjunction with standard antineoplastic therapy ( 1.3 ) Limitations of use Safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions have not been established. ( 1.4 )

How it works

The principal pharmacologic action of pamidronate disodium is inhibition of bone resorption. Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action. Pamidronate disodium adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may block dissolution of this mineral component of bone. In vitro , pamidronate disodium inhibited osteoclast activity. In animal studies, pamidronate disodium inhibited bone resorption, but did not inhibit bone formation and mineralization. In animal tumor models, pamidronate disodium inhibited the increased osteoclast activity induced by tumors.

Contraindications

Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. Reactions to pamidronate disodium injection and to mannitol have included anaphylaxis.

Common side effects

Hypercalcemia of malignancy (≥ 15%); S disease (≥ 10%); Or osteolytic lesions of multiple myeloma (≥ 30%); Patients (2%); Ltiple myeloma the most commonly reported (> 15%)

Adverse reactions

The following adverse reactions are described, or described in greater detail, in other sections: - Deterioration in renal function [see Warnings and Precautions (5.1) ] - Electrolyte disorders [see Warnings and Precautions (5.3) ] - Osteonecrosis of the jaw [see Warnings and Precautions (5.4) ] - Atypical fractures of the femur [see Warnings and Precautions (5.5) ]

Dosage and administration

Hypercalcemia of malignancy: 60 mg to 90 mg pamidronate disodium as a single dose infused over 2 hours to 24 hours for moderate hypercalcemia, or 90 mg as a single dose infused over 2 hours to 24 hours for severe hypercalcemia. If warranted, retreat after a minimum of 7 days. ( 2.1 ) • Paget’s disease of bone: 30 mg pamidronate disodium daily as a 4-hour infusion on 3 consecutive days. ( 2.2 ) • Osteolytic Bone Metastases of Breast Cancer: 90 mg pamidronate disodium as a 2-hour infusion every 3 to 4 weeks. Retreat after recovery of renal function. ( 2.3 ) • Osteolytic Bone Lesions of Multiple Myeloma: 90 mg pamidronate disodium as a 4-hour infusion once every four weeks. Retreat after recovery of renal function. ( 2.3 ) • Administer through a separate infusion line. Do not allow pamidronate disodium infusion to come in contact with any calcium or divalent cation-containing solutions. ( 2.6 )

Drug interactions

Nephrotoxic drugs: Use with caution. ( 7.1 ) • Thalidomide: Increased risk of renal dysfunction in patients with multiple myeloma. ( 7.2 )

Common questions

What is Pamidronate approved to treat?

According to its FDA label, Pamidronate is approved for: Pamidronate disodium is a bisphosphonate indicated for the treatment of: • moderate or severe hypercalcemia associated with malignancy, with or without bone metastases ( 1.1 ) • patients with moderate to severe Paget’s disease of bone ( 1.2 ) • osteolytic bone metastases of breas… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Pamidronate?

Pamidronate belongs to the Bisphosphonate class of medications.

What form does Pamidronate come in?

The FDA label lists Pamidronate as: Renal failure: Do not exceed single doses of 90 mg pamidronate disodium. Assess renal function before each treatment. In patients with bone metastases with severe renal impairment, use of pamidronate disodium is not recommended. ( 5.1 ) • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.2 , 8.1 , 8.3 ) • Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. ( 5.3 ) • Osteonecrosis of the jaw: Perform preventive dental procedures prior to initiating pamidronate disodium. Avoid invasive procedures if possible in patients receiving pamidronate disodium. ( 5.4 ) • Atypical fractures of the femur can occur after minimal or no trauma. Evaluate patients with thigh or groin pain for possible fracture. ( 5.5 ); intravenous route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Pamidronate?

Yes. A generic version of Pamidronate is available in the U.S. Ask your pharmacist about substitution.

Does Pamidronate have a Boxed Warning?

Our ingest of the FDA label for Pamidronate does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

Is Pamidronate currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Pamidronate in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Pamidronate approved by the FDA?

The FDA record lists the approval date for Pamidronate as 2008-10-31.

Who makes Pamidronate?

The FDA label lists Mylan Institutional LLC as a labeler/manufacturer of Pamidronate. Multiple firms may market generics of the same molecule.

How should Pamidronate be stored?

The FDA label states: "Pamidronate Disodium Injection is available as follows: 30 mg/10 mL (3 mg/mL) single-dose vial as a clear-colorless solution containing 30 mg of pamidronate disodium and 470 mg of mannitol in 10 mL water for injection. N…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…